These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1333789)

  • 1. Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
    Miles DW; Aderka D; Engelmann H; Wallach D; Balkwill FR
    Br J Cancer; 1992 Dec; 66(6):1195-9. PubMed ID: 1333789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
    Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
    Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma.
    Bemelmans MH; Gouma DJ; Buurman WA
    J Immunol; 1993 Nov; 151(10):5554-62. PubMed ID: 8228246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2.
    Miles D; Thomsen L; Balkwill F; Thavasu P; Moncada S
    Eur J Clin Invest; 1994 Apr; 24(4):287-90. PubMed ID: 8050458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Soluble TNF and IL-2 receptors in patients with breast carcinoma].
    Tesarová P; Kvasnicka J; Umlaufová A; Homolková J; Jirsa M; Tesar V
    Cas Lek Cesk; 1998 May; 137(11):341-5. PubMed ID: 9727208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble TNF and IL-2 receptors in patients with breast cancer.
    Tesarová P; Kvasnicka J; Umlaufová A; Homolková H; Jirsa M; Tesar V
    Med Sci Monit; 2000; 6(4):661-7. PubMed ID: 11208388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
    Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
    J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy.
    Barrera P; Boerbooms AM; Janssen EM; Sauerwein RW; Gallati H; Mulder J; de Boo T; Demacker PN; van de Putte LB; van der Meer JW
    Arthritis Rheum; 1993 Aug; 36(8):1070-9. PubMed ID: 8393676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever.
    Steinshamn S; Brekke OL; Waage A
    Br J Haematol; 1995 Apr; 89(4):719-24. PubMed ID: 7772508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy.
    Belldegrun A; Pierce W; Sayah D; deKernion J; Wallach D; Aderka D; Figlin RA
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):175-80. PubMed ID: 8385988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis.
    Kornelisse RF; Savelkoul HF; Mulder PH; Suur MH; van der Straaten PJ; van der Heijden AJ; Sukhai RN; Hählen K; Neijens HJ; de Groot R
    J Infect Dis; 1996 Jun; 173(6):1498-502. PubMed ID: 8648229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.
    Kato A; Odamaki M; Takita T; Furuhashi M; Maruyama Y; Hishida A
    Nephrol Dial Transplant; 2001 Sep; 16(9):1838-44. PubMed ID: 11522867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.
    McIntyre CA; Chapman K; Reeder S; Dorreen MS; Bruce L; Rodgers S; Hayat K; Schreenivasan T; Sheridan E; Hancock BW
    Eur J Cancer; 1992; 28(1):58-63. PubMed ID: 1567693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
    Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F
    Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha.
    Karkar AM; Smith J; Pusey CD
    Nephrol Dial Transplant; 2001 Mar; 16(3):518-24. PubMed ID: 11239025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells.
    Vey E; Burger D; Dayer JM
    Eur J Immunol; 1996 Oct; 26(10):2404-9. PubMed ID: 8898953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of proinflammatory cytokine inhibitors (sTNFR I, sTNFR II, IL-1 ra), anti-inflammatory cytokines (IL-10, IL-13) and activation of neutrophils after burn-induced inflammation.
    Sikora JP; Chlebna-Sokół D; Andrzejewska E; Chrul S; Polakowska E; Wysocka A; Sikora A
    Scand J Immunol; 2008 Aug; 68(2):145-52. PubMed ID: 18702744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
    Robak T; Gladalska A; Stepień H
    Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
    Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
    Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.